Locally Advanced Non-Small Cell Lung Cancer
Also known as: Locally Advanced Non Small Cell Lung Cancer (NSCLC) / Locally Advanced Non Small Cell Lung Cancer (NSCLC)* / Locally Advanced NSCLC / Locally advanced Non small cell lung cancer / Locally Advanced Lung Non-Small Cell Carcinoma / Lung Cancer Non-Small Cell Stage III / Nonsmall Cell Lung Cancer Stage III / Non Small Cell Lung Cancer Stage III / Non-Small Cell Lung Cancer (Stage III) / Stage III Non-small-Cell Lung Cancer / Non Small Cell Lung Cancer (Stage III) / Stage III Non-Small Cell Lung Cancer / Non-small Cell Lung Cancer, Stage III / NSCLC, Stage III / Stage III NSCLC / Non-small Cell Lung Cancer Stage III / Stage 3 Non-small cell lung cancer
|A KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy.
|An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
|A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
|A digestive enzyme supplement used as supportive therapy to manage the side effects associated with conventional chemotherapy, radiotherapy, and hormone therapy.
|An oral kinase inhibitor targeted against EGFR and used in the treatment of NSCLC with EGFR exon 20 insertion mutations.
|A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
|A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.
|An experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer.
|A vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC.